⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2625547 | 0.75 | NLRP3 (0.38) | — | |
| SCHEMBL277999 | 0.72 | TSHR (0.31) | — | |
| SCHEMBL21025169 | 0.72 | NLRP3 (0.32) | — | |
| SCHEMBL15901572 | 0.69 | LMNA (0.32) | — | |
| SCHEMBL14261830 | 0.69 | LMNA (0.32) | — | |
| Hydrochloric Acid SCHEMBL4307349 | 0.69 | KDM4E (0.30) | — | |
| SCHEMBL680277 | 0.67 | NLRP3 (0.39) | — | |
| SCHEMBL19580301 | 0.67 | CYP2D6 (0.43) | — | |
| SCHEMBL4323856 | 0.67 | — | — | |
| SCHEMBL22815004 | 0.67 | CYP2C9 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829458-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-10646488-B2 | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190284144-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2019-09-19 | — | — | US | disclosed |
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180015087-A1 | CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-01-18 | — | — | US | disclosed |